These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12173783)

  • 1. HIV-1, HAART and bone metabolism.
    Borderi M; Farneti B; Tampellini L; Giuliani R; Verucchi G; Vescini F; Caudarella R; Chiodo F
    New Microbiol; 2002 Jul; 25(3):375-84. PubMed ID: 12173783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G; Spanu A; Solinas P; Calia GM; Lovigu C; Chessa F; Mannazzu M; Falchi A; Mura MS; Madeddu G
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.
    Rose H; Woolley I; Hoy J; Dart A; Bryant B; Mijch A; Sviridov D
    Metabolism; 2006 Jan; 55(1):90-5. PubMed ID: 16324925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging bone problems in patients infected with human immunodeficiency virus.
    Mondy K; Tebas P
    Clin Infect Dis; 2003 Apr; 36(Suppl 2):S101-5. PubMed ID: 12652379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone disorders in human immunodeficiency virus infection.
    Glesby MJ
    Clin Infect Dis; 2003; 37 Suppl 2():S91-5. PubMed ID: 12942380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolic puzzle during the evolution of HIV infection.
    Salas-Salvadó J; García-Lorda P
    Clin Nutr; 2001 Oct; 20(5):379-91. PubMed ID: 11534932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone metabolism in children with human immunodeficiency virus infection receiving highly active anti-retroviral therapy including a protease inhibitor.
    Tan BM; Nelson RP; James-Yarish M; Emmanuel PJ; Schurman SJ
    J Pediatr; 2001 Sep; 139(3):447-51. PubMed ID: 11562628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of anitiretroviral therapy on bone tissue metabolism in patients with HIV].
    Olczak A; Pawłowska M; Drózdz W
    Przegl Epidemiol; 2008; 62(1):155-62. PubMed ID: 18536239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing issues related to antiretroviral therapy.
    Lesho EP; Gey DC
    Am Fam Physician; 2003 Aug; 68(4):675-86. PubMed ID: 12952384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction.
    Francisci D; Giannini S; Baldelli F; Leone M; Belfiori B; Guglielmini G; Malincarne L; Gresele P
    AIDS; 2009 Mar; 23(5):589-96. PubMed ID: 19177019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Alteration of bone metabolism in HIV-infected patients treated by HAART].
    Giot JB; Franchimont N; Moutschen M
    Rev Med Liege; 2003 Mar; 58(3):155-63. PubMed ID: 12723509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteonecrosis complicating highly active antiretroviral therapy in patients infected with human immunodeficiency virus.
    Monier P; McKown K; Bronze MS
    Clin Infect Dis; 2000 Dec; 31(6):1488-92. PubMed ID: 11096017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis in patients with human immunodeficiency virus type 1 infection in Taiwan.
    Ho YC; Shih TT; Lin YH; Hsiao CF; Chen MY; Hsieh SM; Sheng WH; Sun HY; Hung CC; Chang SC
    Jpn J Infect Dis; 2007 Nov; 60(6):382-6. PubMed ID: 18032839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002).
    Martin K; Lawson-Ayayi S; Miremont-Salamé G; Blaizeau MJ; Balestre E; Lacoste D; Ragnaud JM; Malvy D; Dupon M; Mercié P; Schaeverbeke T; Haramburu F; Dabis F;
    HIV Med; 2004 Nov; 5(6):421-6. PubMed ID: 15544694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.